In this regard, the widely reported decrease in plasma [Trp] with the concomitant increases in [Kyn] and the [Kyn]/[Trp] ratio, and the many preclinical studies and clinical trials of IDO/TDO inhibitors strongly suggest that activities of these two rate-limiting KP enzymes are increased in various cancer types. This evidence concerns the gene TDO2 and cancer.